Wealth Enhancement Advisory Services
ALXN

Wealth Enhancement Advisory Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,742
Closed -$1.49M – 280
2019
Q4 		$1.49M Sell
13,742
-217
-2% -$23.2K 0.05% 137
2019
Q3 		$1.39M Buy
+13,959
New +$1.57M 0.06% 128

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Wealth Enhancement Advisory Services's ALXN Position: Q1 2020 in Review

Wealth Enhancement Advisory Services sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 13,742 shares — an estimated $1.49M sold.

Wealth Enhancement Advisory Services first reported a position in ALXN in Q3 2019 and held it in 2 quarters. The position peaked at $1.49M in Q4 2019. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Wealth Enhancement Advisory Services reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 13,742 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.49M.
  • Wealth Enhancement Advisory Services first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's Alexion Pharmaceuticals position peaked at $1.49M in Q4 2019.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2020, filed 1 May 2020.